Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Role of the EBMT registry on reporting CAR T-cell outcomes

Christian Chabannon • 31 Aug 2020
EBMT 2020
General CAR-T

Christian Chabannon, MD, PhD, Aix Marseille University (AMU) School of Medicine, Marseille, France, outlines the role of the European Society for Blood and Marrow Transplantation (EBMT) registry on reporting on CAR T-cell outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christian Chabannon

2:17
Improving access to advanced therapies: the access to CAR-T in Europe
Christian Chabannon • 17 Feb 2024
1:33
Addressing the changing needs for ad-hoc resources for safe delivery of advanced therapies
Christian Chabannon • 17 Feb 2024
1:36
IFM-2015-03: plerixafor before salvage ASCT in R/R myeloma
Christian Chabannon • 21 Oct 2023
2:21
Practical considerations for DLI after haploidentical SCT
Christian Chabannon • 21 Oct 2023

Related Videos

1:08
Chronological age no longer dictates eligibility for allogeneic transplantation in patients with MDS
Didier Blaise • 4 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
2:44
Do biomarkers exist for predicting response to CAR T-cell therapy?
Marco Ruella • 9 Apr 2024
2:43
Resistance to CAR T-cell therapy
Marco Ruella • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals